# US 11,026,968 B2 · Anticoagulation fluid comprising citrate and phosphate > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,026,968 B2 - Document ID: US11026968B2 - Status: Granted - Kind: B2 - Application number: 16/576,301 - Filed: 2019-09-19 - Published: 2020-01-09 - Granted: 2021-06-08 - Earliest claimed: 2013-04-30 - Assignees: Gambro Lundia AB - Applicants: Gambro Lundia AB - Inventors: Jan Sternby; Anders Wieslander - Web page: https://patentgrep.com/patent/US11026968B2 ## CPC - A61K 33/42: Phosphorus; Compounds thereof - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid - A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms - A61K 33/00: Medicinal preparations containing inorganic active ingredients - A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay} - A61K 33/10: Carbonates; Bicarbonates - A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides - A61M 1/1654: {Dialysates therefor} - A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors - A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention concerns an anticoagulation fluid comprising 10-40 mM citrate and 0.1-4 mM phosphate. The anticoagulation fluid is to be used for regional citrate anticoagulation in an extracorporeal blood circuit. The anticoagulation fluid may be combined with at least one treatment fluid in a dialysis treatment, and it may be included in a system for regional citrate anticoagulation in an extracorporeal blood circuit. ## Claims ### Claim 1 A single compartment bag comprising an anticoagulation fluid for regional citrate anticoagulation in an extracorporeal blood circuit, wherein the anticoagulation fluid in the single compartment bag comprises 18-40 mM basic citrate; 0.1-5 mM acid citrate; 0.5-1.5 mM total calcium; and 0.1-3 mM phosphate, the anticoagulation fluid having a pH between 7.4 and 8. ### Claim 2 (depends on 1) The single compartment bag according to claim 1, wherein the anticoagulation fluid comprises 20-40 mM basic citrate. ### Claim 3 (depends on 1) The single compartment bag according to claim 1, wherein the anticoagulation fluid comprises 0.5-2.0 mM phosphate. ### Claim 4 (depends on 1) The single compartment bag according to claim 1, wherein the anticoagulation fluid comprises 0.8-2 mM phosphate. ### Claim 5 (depends on 1) The single compartment bag according to claim 1, wherein the anticoagulation fluid comprises 0-150 mM sodium. ### Claim 6 (depends on 1) The single compartment bag according to claim 1, wherein the anticoagulation fluid comprises 1.5-4 mM calcium, 0-5.0 mM potassium, 0-11 mM glucose, and 0-150 mM sodium. ### Claim 7 (depends on 1) The single compartment bag according to claim 1, wherein the anticoagulation fluid comprises 18 mM basic citrate. ### Claim 8 (depends on 1) The single compartment bag according to claim 1, wherein the anticoagulation fluid comprises 0.1 mM acid citrate. ### Claim 9 (depends on 6) The single compartment bag according to claim 6, wherein the anticoagulation fluid comprises 1.5-4.0 mM calcium. ### Claim 10 (depends on 1) The single compartment bag according to claim 1, wherein the anticoagulation fluid comprises 2.0-3.0 mM total calcium. ### Claim 11 (depends on 10) The single compartment bag according to claim 10, wherein the anticoagulation fluid comprises 2.2-2.4 mM total calcium. ### Claim 12 (depends on 1) The single compartment bag according to claim 1, wherein the anticoagulation fluid further comprises 0.1-11 mM glucose. ### Claim 13 (depends on 1) The single compartment bag according to claim 1, wherein the anticoagulation fluid comprises 0.8-1.2 mM phosphate. ### Claim 14 A single compartment bag comprising an anticoagulation fluid for regional citrate anticoagulation in an extracorporeal blood circuit, wherein the anticoagulation fluid in the single compartment bag comprises 18-40 mM basic citrate; 0.1-5 mM acid citrate; 0.1-11 mM glucose; and 0.1-3 mM phosphate, the anticoagulation fluid having a pH between 7.4 and 8.